US › Healthcare

Senti Biosciences Inc (SNTI)

US · Healthcare · Biotechnology

$0.16-2.74%

Last close · 2026-11-06

Latest quarter · ended 2026-06-30

Revenue

$17,000

Net profit

$-12.8M

EPS

$-0.41

EPS estimate

$-0.33

Net margin

-75,000.0%

EPS came in at -0.41 against a street estimate of -0.33 — a miss of 24.2%.

Key statistics

Market cap

$6.3M

Forward P/E

0.0

P/B

5.45

Book value

$-0.11

EPS (TTM)

$-1.72

52-week high

$2.48

52-week low

$0.15

50-day MA

$0.28

200-day MA

$0.71

Beta

2.32

Analyst view

Analysts rate Senti Biosciences Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $13.50.

Shareholding

Insiders

47.87%

Institutions

19.03%

Largest institutional holders

Fund	Stake
Nantahala Capital Management, LLC	2.85%
Vanguard Capital Management, LLC	1.73%
Geode Capital Management, LLC	0.60%
Citadel Advisors Llc	0.34%
Vanguard Fiduciary Trust Co	0.29%
Jane Street Group LLC	0.17%
Menlo Ventures Management, L.P.	0.11%
Northern Trust Corp	0.10%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Senti Biosciences Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-11-07.